Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome.

Item

http://www.wikidata.org/entity/Q37409121

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Comparison clinical and metabo ...... in polycystic ovary syndrome.

@en

Comparison clinical and metabo ...... in polycystic ovary syndrome.

@nl

type

Item

label

Comparison clinical and metabo ...... in polycystic ovary syndrome.

@en

Comparison clinical and metabo ...... in polycystic ovary syndrome.

@nl

prefLabel

Comparison clinical and metabo ...... in polycystic ovary syndrome.

@en

Comparison clinical and metabo ...... in polycystic ovary syndrome.

@nl

P1476

Comparison clinical and metabo ...... in polycystic ovary syndrome.

@en

P2093

Karoon Shahebrahimi

http://www.w3.org/2001/XMLSchema#string

Mansour Rezaei

http://www.w3.org/2001/XMLSchema#string

Nasrin Jalilian

http://www.w3.org/2001/XMLSchema#string

P2860

Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS.

Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.

Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.

State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS).

Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.

Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.

A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.

Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS).

Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months.

P304

805-809

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/2230-8210.192925

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nasrin Bazgir

P577

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27867884

http://www.w3.org/2001/XMLSchema#string

P921

metformin

polycystic ovary syndrome

P932

5105565

http://www.w3.org/2001/XMLSchema#string